Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis: The Atherosclerosis Lesion Progression Intervention Using Niacin Extended Release in Saphenous Vein Grafts (ALPINE-SVG) Pilot Trial
Brief Summary: Intermediate saphenous vein graft (SVG) lesions are common, have high rates of progression to severe lesions or occlusion, and are associated with high incidence of adverse clinical outcomes.

The ALPINE-SVG trial is a randomized-controlled trial of extended-release niacin vs. placebo in patients with intermediate saphenous vein graft lesions. The main hypothesis of the study is that compared to placebo, niacin administration will result in reduction in percent atheroma volume at 12-month follow-up angiography.


Options:
A: Arm Label: Extended-release niacin; Type: EXPERIMENTAL; Interventions: Drug: extended-release niacin (Niaspan) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: extended-release niacin (Niaspan) | Intervention Type: DRUG; Name: extended-release niacin (Niaspan); Assigned to Arm(s): Extended-release niacin, Placebo
B: Arm Label: Part 1 - Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: ezetimibe/simvastatin + niacin (ER) | Arm Label: Part 1 -Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: ezetimibe (+) simvastatin, Drug: Comparator: Placebo to Niacin (ER) | Arm Label: Part 1 - Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Placebo to ezetimibe/simvastatin, Drug: Comparator: niacin (ER) tablet | Arm Label: Part 2 - Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: ezetimibe/simvastatin and niacin (ER) | Arm Label: Part 2 - Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: ezetimibe and simvastatin, Drug: Comparator: Placebo to niacin (ER) | Intervention Type: DRUG; Name: Comparator: ezetimibe/simvastatin + niacin (ER); Assigned to Arm(s): Part 1 - Arm 1 | Intervention Type: DRUG; Name: Comparator: Placebo to ezetimibe/simvastatin; Assigned to Arm(s): Part 1 - Arm 3 | Intervention Type: DRUG; Name: Comparator: niacin (ER) tablet; Assigned to Arm(s): Part 1 - Arm 3 | Intervention Type: DRUG; Name: Comparator: ezetimibe (+) simvastatin; Assigned to Arm(s): Part 1 -Arm 2 | Intervention Type: DRUG; Name: Comparator: Placebo to Niacin (ER); Assigned to Arm(s): Part 1 -Arm 2 | Intervention Type: DRUG; Name: Comparator: ezetimibe/simvastatin and niacin (ER); Assigned to Arm(s): Part 2 - Arm 1 | Intervention Type: DRUG; Name: Comparator: ezetimibe and simvastatin; Assigned to Arm(s): Part 2 - Arm 2 | Intervention Type: DRUG; Name: Comparator: Placebo to niacin (ER); Assigned to Arm(s): Part 2 - Arm 2
C: Intervention Type: DRUG; Name: Niaspan; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebos | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Other: Placebos | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Other: Placebos | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Fenofibrate, Other: Placebos | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Behavioral: Exercise, Drug: Niacin, Drug: Fenofibrate | Intervention Type: BEHAVIORAL; Name: Diet; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 2, 3, 4, 5 | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): 3, 5 | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): 4, 5 | Intervention Type: OTHER; Name: Placebos; Assigned to Arm(s): 1, 2, 3, 4

Answer: A